BIODESIX, INC. Selling, General and Administrative Expense
BIODESIX, INC. (BDSX) reported Selling, General and Administrative Expense of $24.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- BIODESIX, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $24.28M, a 8.35% increase year-over-year.
- BIODESIX, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $24.26M, a 18.65% increase year-over-year.
- BIODESIX, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $22.97M, a 13.62% increase year-over-year.
- BIODESIX, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $21.71M, a 8.48% increase year-over-year.
- BIODESIX, INC. selling, general and administrative expense for fiscal 2025 was $87.55M, a 8.82% increase from fiscal 2024.
- BIODESIX, INC. selling, general and administrative expense for fiscal 2024 was $80.45M, a 19.39% increase from fiscal 2023.
- BIODESIX, INC. selling, general and administrative expense for fiscal 2023 was $67.39M, a 9.64% increase from fiscal 2022.
- BIODESIX, INC. selling, general and administrative expense for fiscal 2022 was $61.46M, a 21.67% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.28M 10-Q · filed 2026-08-05 | $48.54M 10-Q · filed 2026-08-05 | $71.52M derived: sum of 3 quarters · filed 2026-08-05 | $93.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $24.26M 10-Q · filed 2026-05-04 | $47.23M derived: sum of 2 quarters · filed 2026-05-04 | $68.95M derived: sum of 3 quarters · filed 2026-05-04 | $91.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $22.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $44.69M derived: sum of 2 quarters · filed 2026-02-26 | $67.10M derived: sum of 3 quarters · filed 2026-08-05 | $87.55M 10-K · filed 2026-02-26 |
| 2025-09-30 | $21.71M 10-Q · filed 2025-11-03 | $44.13M derived: sum of 2 quarters · filed 2026-08-05 | $64.57M 10-Q · filed 2025-11-03 | $84.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $22.41M 10-Q · filed 2026-08-05 | $42.86M 10-Q · filed 2026-08-05 | $63.08M derived: sum of 3 quarters · filed 2026-08-05 | $83.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $20.45M 10-Q · filed 2026-05-04 | $40.67M derived: sum of 2 quarters · filed 2026-05-04 | $60.68M derived: sum of 3 quarters · filed 2026-05-04 | $80.34M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $20.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $40.23M derived: sum of 2 quarters · filed 2026-02-26 | $59.90M derived: sum of 3 quarters · filed 2026-02-26 | $80.45M 10-K · filed 2026-02-26 |
| 2024-09-30 | $20.02M 10-Q · filed 2025-11-03 | $39.68M derived: sum of 2 quarters · filed 2025-11-03 | $60.23M 10-Q · filed 2025-11-03 | $76.48M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $19.66M 10-Q · filed 2025-08-07 | $40.22M 10-Q · filed 2025-08-07 | $56.47M derived: sum of 3 quarters · filed 2025-08-07 | $71.96M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $20.56M 10-Q · filed 2025-05-13 | $36.81M derived: sum of 2 quarters · filed 2025-05-13 | $52.30M derived: sum of 3 quarters · filed 2025-05-13 | $68.95M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $16.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $31.75M derived: sum of 2 quarters · filed 2025-03-03 | $48.40M derived: sum of 3 quarters · filed 2025-03-03 | $67.39M 10-K · filed 2025-03-03 |
| 2023-09-30 | $15.50M 10-Q · filed 2024-11-01 | $32.15M derived: sum of 2 quarters · filed 2024-11-01 | $51.14M 10-Q · filed 2024-11-01 | $67.76M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $16.65M 10-Q · filed 2024-08-07 | $35.64M 10-Q · filed 2024-08-07 | $52.27M derived: sum of 3 quarters · filed 2024-08-07 | $67.38M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $18.99M 10-Q · filed 2024-05-08 | $35.62M derived: sum of 2 quarters · filed 2024-05-08 | $50.73M derived: sum of 3 quarters · filed 2024-05-08 | $65.96M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $16.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $31.74M derived: sum of 2 quarters · filed 2024-03-01 | $46.98M derived: sum of 3 quarters · filed 2024-03-01 | $61.46M 10-K · filed 2024-03-01 |
| 2022-09-30 | $15.11M 10-Q · filed 2023-11-07 | $30.35M derived: sum of 2 quarters · filed 2023-11-07 | $44.84M 10-Q · filed 2023-11-07 | $58.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $15.23M 10-Q · filed 2023-08-07 | $29.72M 10-Q · filed 2023-08-07 | $43.28M derived: sum of 3 quarters · filed 2023-08-07 | $56.89M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $14.49M 10-Q · filed 2023-05-11 | $28.05M derived: sum of 2 quarters · filed 2023-05-11 | $41.65M derived: sum of 3 quarters · filed 2023-05-11 | $53.08M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $13.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $27.16M derived: sum of 2 quarters · filed 2023-03-06 | $38.59M derived: sum of 3 quarters · filed 2023-03-06 | $50.52M 10-K · filed 2023-03-06 |
| 2021-09-30 | $13.61M 10-Q · filed 2022-11-03 | $25.03M derived: sum of 2 quarters · filed 2022-11-03 | $36.96M 10-Q · filed 2022-11-03 | $49.02M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $11.43M 10-Q · filed 2022-08-04 | $23.35M 10-Q · filed 2022-08-04 | $35.42M derived: sum of 3 quarters · filed 2022-08-04 | $43.30M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $11.93M 10-Q · filed 2022-05-11 | $23.99M derived: sum of 2 quarters · filed 2022-05-11 | $31.87M derived: sum of 3 quarters · filed 2022-05-11 | $38.70M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $12.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $19.94M derived: sum of 2 quarters · filed 2022-03-14 | $26.78M derived: sum of 3 quarters · filed 2022-03-14 | $34.86M 10-K · filed 2022-03-14 |
| 2020-09-30 | $7.88M 10-Q · filed 2021-11-15 | $14.71M derived: sum of 2 quarters · filed 2021-11-15 | $22.79M 10-Q · filed 2021-11-15 | $29.35M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $6.83M 10-Q · filed 2021-08-10 | $14.91M 10-Q · filed 2021-08-10 | $21.47M derived: sum of 3 quarters · filed 2021-08-10 | $29.68M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $8.08M 10-Q · filed 2021-05-11 | $14.64M derived: sum of 2 quarters · filed 2021-05-11 | $22.85M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $14.77M derived: sum of 2 quarters · filed 2021-03-16 | $30.64M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $8.21M 10-Q · filed 2020-12-10 | $24.08M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |